The "digital phenotype," a catch-all term for the trail of relevant health data people leave behind in their interactions with the internet, social media, and technology, has largely untapped potential for the early detection of various conditions.
A new editorial in Nature Biotech poses the idea of the “digital phenotype” as a catch-all term for the trail of relevant health data people leave behind in their interactions with the internet, social media, and technology, which has largely untapped potential for the early detection of various conditions.
CareMore Chief Medical Officer Sachin Jain, MD, submitted the paper along with Harvard Medical School colleagues Brian Powers, an MD candidate, Jared Hawkins, PhD, and John Brownstein, PhD, whose Computational Epidemiology Group has done a lot of work in the area of digital phenotyping already.
“People are increasingly leaving a footprint of their health status through technology, including social media, forums, online communities, wearable technologies, and mobile devices,” Dr Jain said in a statement. “This information all has clinical value to a physician. The challenge is being aware of it and knowing how to access and interpret it.”
Read more at MobiHealthNews: http://bit.ly/1bMrKBU
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More